<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM">
      <PMID Version="2">33989635</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1083-351X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>297</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of biological chemistry</Title>
          <ISOAbbreviation>J Biol Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template.</ArticleTitle>
        <Pagination>
          <StartPage>100770</StartPage>
          <MedlinePgn>100770</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">100770</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbc.2021.100770</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0021-9258(21)00563-9</ELocationID>
        <Abstract>
          <AbstractText>The RNA-dependent RNA polymerase of the severe acute respiratory syndrome coronavirus 2 is an important target in current drug development efforts for the treatment of coronavirus disease 2019. Molnupiravir is a broad-spectrum antiviral that is an orally bioavailable prodrug of the nucleoside analogue β-D-N<sup>4</sup>-hydroxycytidine (NHC). Molnupiravir or NHC can increase G to A and C to U transition mutations in replicating coronaviruses. These increases in mutation frequencies can be linked to increases in antiviral effects; however, biochemical data of molnupiravir-induced mutagenesis have not been reported. Here we studied the effects of the active compound NHC 5'-triphosphate (NHC-TP) against the purified severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase complex. The efficiency of incorporation of natural nucleotides over the efficiency of incorporation of NHC-TP into model RNA substrates followed the order GTP (12,841) &gt; ATP (424) &gt; UTP (171) &gt; CTP (30), indicating that NHC-TP competes predominantly with CTP for incorporation. No significant inhibition of RNA synthesis was noted as a result of the incorporated monophosphate in the RNA primer strand. When embedded in the template strand, NHC-monophosphate supported the formation of both NHC:G and NHC:A base pairs with similar efficiencies. The extension of the NHC:G product was modestly inhibited, but higher nucleotide concentrations could overcome this blockage. In contrast, the NHC:A base pair led to the observed G to A (G:NHC:A) or C to U (C:G:NHC:A:U) mutations. Together, these biochemical data support a mechanism of action of molnupiravir that is primarily based on RNA mutagenesis mediated via the template strand.</AbstractText>
          <CopyrightInformation>Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gordon</LastName>
            <ForeName>Calvin J</ForeName>
            <Initials>CJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tchesnokov</LastName>
            <ForeName>Egor P</ForeName>
            <Initials>EP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schinazi</LastName>
            <ForeName>Raymond F</ForeName>
            <Initials>RF</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Biochemical Pharmacology, Department of Pediatrics, Center for AIDS Research, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Götte</LastName>
            <ForeName>Matthias</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada; Li Ka Shing Institute of Virology at University of Alberta, Edmonton, Alberta, Canada. Electronic address: gotte@ualberta.ca.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30 AI050409</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>05</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Biol Chem</MedlineTA>
        <NlmUniqueID>2985121R</NlmUniqueID>
        <ISSNLinking>0021-9258</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006898">Hydroxylamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5CSZ8459RP</RegistryNumber>
          <NameOfSubstance UI="D003562">Cytidine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>C3D11PV2O4</RegistryNumber>
          <NameOfSubstance UI="C010737">N(4)-hydroxycytidine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YA84KI1VEW</RegistryNumber>
          <NameOfSubstance UI="C000656703">molnupiravir</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
          <QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003562" MajorTopicYN="N">Cytidine</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006898" MajorTopicYN="N">Hydroxylamines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016296" MajorTopicYN="N">Mutagenesis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017354" MajorTopicYN="N">Point Mutation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Covid-19</Keyword>
        <Keyword MajorTopicYN="Y">RNA-dependent RNA polymerase</Keyword>
        <Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword>
        <Keyword MajorTopicYN="Y">antiviral agent</Keyword>
        <Keyword MajorTopicYN="Y">coronavirus</Keyword>
        <Keyword MajorTopicYN="Y">drug development</Keyword>
        <Keyword MajorTopicYN="Y">mutagen</Keyword>
        <Keyword MajorTopicYN="Y">nucleoside analogue</Keyword>
      </KeywordList>
      <CoiStatement>Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>20</Hour>
          <Minute>9</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33989635</ArticleId>
        <ArticleId IdType="pmc">PMC8110631</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jbc.2021.100770</ArticleId>
        <ArticleId IdType="pii">S0021-9258(21)00563-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>U.S. Food and Drug Administration  . U.S. Food and Drug Administration; Silver Spring, MD: 2020. Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Remdesivir (GS-5734TM)</Citation>
        </Reference>
        <Reference>
          <Citation>Gordon C.J., Tchesnokov E.P., Woolner E., Perry J.K., Feng J.Y., Porter D.P., Gotte M. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J. Biol. Chem. 2020;295:6785–6797.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7242698</ArticleId>
            <ArticleId IdType="pubmed">32284326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>U.S. Food and Drug Administration  . U.S. Food and Drug Administration; Silver Spring, MD: 2020. Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Casirivimab and Imdevimab.</Citation>
        </Reference>
        <Reference>
          <Citation>Vasudevan N., Ahlqvist G.P., McGeough C.P., Paymode D.J., Cardoso F.S.P., Lucas T., Dietz J.P., Opatz T., Jamison T.F., Gupton F.B., Snead D.R. A concise route to MK-4482 (EIDD-2801) from cytidine. Chem. Commun. (Camb.) 2020;56:13363–13364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33030468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stuyver L.J., Whitaker T., McBrayer T.R., Hernandez-Santiago B.I., Lostia S., Tharnish P.M., Ramesh M., Chu C.K., Jordan R., Shi J., Rachakonda S., Watanabe K.A., Otto M.J., Schinazi R.F. Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob. Agents Chemother. 2003;47:244–254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC149013</ArticleId>
            <ArticleId IdType="pubmed">12499198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoon J.J., Toots M., Lee S., Lee M.E., Ludeke B., Luczo J.M., Ganti K., Cox R.M., Sticher Z.M., Edpuganti V., Mitchell D.G., Lockwood M.A., Kolykhalov A.A., Greninger A.L., Moore M.L. Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses. Antimicrob. Agents Chemother. 2018;62</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6105843</ArticleId>
            <ArticleId IdType="pubmed">29891600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costantini V.P., Whitaker T., Barclay L., Lee D., McBrayer T.R., Schinazi R.F., Vinje J. Antiviral activity of nucleoside analogues against norovirus. Antivir. Ther. 2012;17:981–991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7751060</ArticleId>
            <ArticleId IdType="pubmed">22910194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reynard O., Nguyen X.N., Alazard-Dany N., Barateau V., Cimarelli A., Volchkov V.E. Identification of a new ribonucleoside inhibitor of Ebola virus replication. Viruses. 2015;7:6233–6240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4690858</ArticleId>
            <ArticleId IdType="pubmed">26633464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urakova N., Kuznetsova V., Crossman D.K., Sokratian A., Guthrie D.B., Kolykhalov A.A., Lockwood M.A., Natchus M.G., Crowley M.R., Painter G.R., Frolova E.I., Frolov I. beta-d-N (4)-Hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome. J. Virol. 2018;92</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5774879</ArticleId>
            <ArticleId IdType="pubmed">29167335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agostini M.L., Pruijssers A.J., Chappell J.D., Gribble J., Lu X., Andres E.L., Bluemling G.R., Lockwood M.A., Sheahan T.P., Sims A.C., Natchus M.G., Saindane M., Kolykhalov A.A., Painter G.R., Baric R.S. Small-molecule antiviral beta-d-N (4)-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J. Virol. 2019;93</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6880162</ArticleId>
            <ArticleId IdType="pubmed">31578288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ehteshami M., Tao S., Zandi K., Hsiao H.M., Jiang Y., Hammond E., Amblard F., Russell O.O., Merits A., Schinazi R.F. Characterization of beta-d-N(4)-hydroxycytidine as a novel inhibitor of Chikungunya virus. Antimicrob. Agents Chemother. 2017;61</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5365705</ArticleId>
            <ArticleId IdType="pubmed">28137799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toots M., Yoon J.J., Cox R.M., Hart M., Sticher Z.M., Makhsous N., Plesker R., Barrena A.H., Reddy P.G., Mitchell D.G., Shean R.C., Bluemling G.R., Kolykhalov A.A., Greninger A.L., Natchus M.G. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci. Transl. Med. 2019;11</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6848974</ArticleId>
            <ArticleId IdType="pubmed">31645453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheahan T.P., Sims A.C., Zhou S., Graham R.L., Pruijssers A.J., Agostini M.L., Leist S.R., Schafer A., Dinnon K.H., 3rd, Stevens L.J., Chappell J.D., Lu X., Hughes T.M., George A.S., Hill C.S. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 2020;12</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7164393</ArticleId>
            <ArticleId IdType="pubmed">32253226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenke K., Hansen F., Schwarz B., Feldmann F., Haddock E., Rosenke R., Barbian K., Meade-White K., Okumura A., Leventhal S., Hawman D.W., Ricotta E., Bosio C.M., Martens C., Saturday G. Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. Nat. Commun. 2021;12:2295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8052374</ArticleId>
            <ArticleId IdType="pubmed">33863887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox R.M., Wolf J.D., Plemper R.K. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat. Microbiol. 2021;6:11–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7755744</ArticleId>
            <ArticleId IdType="pubmed">33273742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wahl A., Gralinski L.E., Johnson C.E., Yao W., Kovarova M., Dinnon K.H., 3rd, Liu H., Madden V.J., Krzystek H.M., De C., White K.K., Gully K., Schafer A., Zaman T., Leist S.R. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature. 2021;591:451–457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7979515</ArticleId>
            <ArticleId IdType="pubmed">33561864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sledziewska E., Janion C. Mutagenic specificity of N4-hydroxycytidine. Mutat. Res. 1980;70:11–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7366595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janion C., Glickman B.W. N-4-Hydroxycytidine - a mutagen specific for at to Gc transitions. Mutat. Res. 1980;72:43–47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6160396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernandez-Santiago B.I., Beltran T., Stuyver L., Chu C.K., Schinazi R.F. Metabolism of the anti-hepatitis C virus nucleoside beta-D-N4-hydroxycytidine in different liver cells. Antimicrob. Agents Chemother. 2004;48:4636–4642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC529212</ArticleId>
            <ArticleId IdType="pubmed">15561837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janion C. On the different response of Salmonella typhimurium hisG46 and TA1530 to mutagenic action of base analogues. Acta Biochim. Pol. 1979;26:171–177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">388954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou S., Hill C.S., Sarkar S., Tse L.V., Woodburn B.M.D., Schinazi R.F., Sheahan T.P., Baric R.S., Heise M.T., Swanstrom R. beta-D-N 4-hydroxycytidine (NHC) inhibits SARS-CoV-2 through lethal mutagenesis but Is also mutagenic to mammalian cells. J Infect Dis. 2021 doi: 10.1093/infdis/jiab247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/infdis/jiab247</ArticleId>
            <ArticleId IdType="pmc">PMC8136050</ArticleId>
            <ArticleId IdType="pubmed">33961695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Painter W.P., Holman W., Bush J.A., Almazedi F., Malik H., Eraut N., Morin M.J., Szewczyk L.J., Painter G.R. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob. Agents Chemother. 2021 doi: 10.1128/AAC.02428-20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.02428-20</ArticleId>
            <ArticleId IdType="pmc">PMC8092915</ArticleId>
            <ArticleId IdType="pubmed">33649113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie X., Muruato A.E., Zhang X., Lokugamage K.G., Fontes-Garfias C.R., Zou J., Liu J., Ren P., Balakrishnan M., Cihlar T., Tseng C.K., Makino S., Menachery V.D., Bilello J.P., Shi P.Y. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. Nat. Commun. 2020;11:5214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7567097</ArticleId>
            <ArticleId IdType="pubmed">33060595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shannon A., Selisko B., Le N.T., Huchting J., Touret F., Piorkowski G., Fattorini V., Ferron F., Decroly E., Meier C., Coutard B., Peersen O., Canard B. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat. Commun. 2020;11:4682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7499305</ArticleId>
            <ArticleId IdType="pubmed">32943628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crotty S., Maag D., Arnold J.J., Zhong W., Lau J.Y., Hong Z., Andino R., Cameron C.E. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 2000;6:1375–1379.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11100123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferron F., Subissi L., Silveira De Morais A.T., Le N.T.T., Sevajol M., Gluais L., Decroly E., Vonrhein C., Bricogne G., Canard B., Imbert I. Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA. Proc. Natl. Acad. Sci. U. S. A. 2018;115:E162–E171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5777078</ArticleId>
            <ArticleId IdType="pubmed">29279395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith E.C., Blanc H., Surdel M.C., Vignuzzi M., Denison M.R. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: Evidence for proofreading and potential therapeutics. PLoS Pathog. 2013;9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3744431</ArticleId>
            <ArticleId IdType="pubmed">23966862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sticher Z.M., Lu G., Mitchell D.G., Marlow J., Moellering L., Bluemling G.R., Guthrie D.B., Natchus M.G., Painter G.R., Kolykhalov A.A. Analysis of the potential for N (4)-hydroxycytidine to inhibit mitochondrial replication and function. Antimicrob. Agents Chemother. 2020;64</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6985706</ArticleId>
            <ArticleId IdType="pubmed">31767721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tchesnokov E.P., Raeisimakiani P., Ngure M., Marchant D., Gotte M. Recombinant RNA-dependent RNA polymerase complex of Ebola virus. Sci. Rep. 2018;8:3970.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5838098</ArticleId>
            <ArticleId IdType="pubmed">29507309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tchesnokov E.P., Feng J.Y., Porter D.P., Gotte M. Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses. 2019;11:326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6520719</ArticleId>
            <ArticleId IdType="pubmed">30987343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tchesnokov E.P., Bailey-Elkin B.A., Mark B.L., Gotte M. Independent inhibition of the polymerase and deubiquitinase activities of the Crimean-Congo Hemorrhagic Fever Virus full-length L-protein. PLoS Negl. Trop. Dis. 2020;14</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7271988</ArticleId>
            <ArticleId IdType="pubmed">32497085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gordon C.J., Tchesnokov E.P., Feng J.Y., Porter D.P., Gotte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J. Biol. Chem. 2020;295:4773–4779.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7152756</ArticleId>
            <ArticleId IdType="pubmed">32094225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deval J., Hong J., Wang G., Taylor J., Smith L.K., Fung A., Stevens S.K., Liu H., Jin Z., Dyatkina N., Prhavc M., Stoycheva A.D., Serebryany V., Liu J., Smith D.B. Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2'-fluoro-4'-chloromethyl-cytidine triphosphate. PLoS Pathog. 2015;11</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4476725</ArticleId>
            <ArticleId IdType="pubmed">26098424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tvarogova J., Madhugiri R., Bylapudi G., Ferguson L.J., Karl N., Ziebuhr J. Identification and characterization of a human coronavirus 229E nonstructural protein 8-associated RNA 3'-terminal adenylyltransferase activity. J. Virol. 2019;93</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6613758</ArticleId>
            <ArticleId IdType="pubmed">30918070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fung A., Jin Z., Dyatkina N., Wang G., Beigelman L., Deval J. Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase. Antimicrob. Agents Chemother. 2014;58:3636–3645.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4068585</ArticleId>
            <ArticleId IdType="pubmed">24733478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jena N.R. Role of different tautomers in the base-pairing abilities of some of the vital antiviral drugs used against COVID-19. Phys. Chem. Chem. Phys. 2020;22:28115–28122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33290476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Traut T.W. Physiological concentrations of purines and pyrimidines. Mol. Cell. Biochem. 1994;140:1–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7877593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tchesnokov E.P., Gordon C.J., Woolner E., Kocinkova D., Perry J.K., Feng J.Y., Porter D.P., Gotte M. Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action. J. Biol. Chem. 2020;295:16156–16165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7681019</ArticleId>
            <ArticleId IdType="pubmed">32967965</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
